Generate:Biomedicines
Generate:Biomedicines is a biotech company pioneering Generative Biology™ using machine learning, biological engineering, and medicine to create novel therapeutics computationally. The company is focused on transforming biotherapeutic development and developing breakthrough medicines.
Headquarters
Somerville, Massachusetts, United States
Company Size
201-500 employees
Generate:Biomedicines is a therapeutics company that combines machine learning, computational biology, and biological engineering to design and develop precision protein medicines and antibodies. Using generative AI and lab-driven engineering, the company builds targeted biologics and epitope-focused candidates, advancing a pipeline from discovery through clinical development. Its clinical-stage programs include GB-0895, a long‑acting anti‑TSLP antibody progressing to global Phase 3 studies, and the company has recently completed an initial public offering. Generate was incubated by Flagship Pioneering and emphasizes platform-driven discovery to accelerate novel biologic therapeutics.
AI Meets Biotech The High Stakes IPO of Generate Biomedicines – The Stillman Exchange
4 days ago
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
2 weeks ago
Generate Biomedicines Shares Plummet After $400 Million Market Debut
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Generate:Biomedicines.
29% above the average for this role
Generate caps a strong month for biotech IPOs with $400M offering
2 weeks ago
Vice President of Clinical Development Operations
Strand Therapeutics
Associate Director of GCP Quality Assurance
Akero Therapeutics
Associate Director, Global Patient Safety Quality and Compliance
Revolution Medicines
Director, Clinical Operations
Absci
Clinical Trial Associate, Oncology, EMEA
Eikon Therapeutics
Executive Director, Global Patient Safety Quality and Compliance - Pharmacovigilance
Revolution Medicines